Ask AI
CDK46 persistence

CE

Case Challenge: Improving Treatment Adherence and Persistence to CDK4/6 Inhibitor Treatment of HR+/HER2- EBC

Pharmacists: 0.50 contact hour (0.05 CEUs)

Released: July 21, 2026

Expiration: January 20, 2027

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A patient with high-risk hormone receptor (HR)–positive/HER2-negative early breast cancer (EBC) requires a dose reduction of adjuvant abemaciclib because of grade 3 diarrhea. She asks whether reducing the dose will make the treatment less effective. 

How would you counsel this patient?

2.

A 58-year-old woman with high-risk HR-positive/HER2-negative EBC is scheduled to start adjuvant ribociclib in combination with endocrine therapy (ET). During your pretreatment medication review, you note that she has been receiving atorvastatin 40 mg daily for several years to manage hyperlipidemia. She has no history of statin intolerance, and her liver function tests are within normal limits.

What is the most appropriate medication intervention before initiating ribociclib?